[NYTimes] ChemGenex Pharmaceuticals found out the hard way how important it is to have a trustworthy companion.

 The Food and Drug Administration last year rejected the company’s drug to treat a subset of leukemia patients whose tumors had a particular genetic mutation. The main problem was not the drug itself, the agency said. Rather, ChemGenex had [...]

[AmedNews] U.S. Supreme Court justices in December heard oral arguments in two high-profile patent cases that could have widespread effects on patients who need certain drugs.
In Mayo Collaborative Services v. Prometheus Laboratories Inc., the high court is weighing whether a test that measures patients’ metabolite levels to determine drug dosages should be patentable. Prometheus sued [...]